Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

Journal of the National Cancer Institute

Volumn 95, Issue 18, 2003, Pages 1376-1383

  D'Amico, Anthony V ^a   Moul, Judd W ^b   Carroll, Peter R ^c   Sun, Leon ^b   Lubeck, Deborah ^c   Chen, Ming Hui ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; HORMONE INHIBITION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; AGE; BLOOD; CONFIDENCE INTERVAL; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK; SURVIVAL; TIME; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0141729468     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg043     Document Type: Article

References (37)

1. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
2. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, et al. Use of second treatment following definitive local therapy for prostate cancer. Data from the CaPSURE database. J Urol 1998;160: 1398-404.
3. D'Amico AV. Predicting prostate-specific antigen recurrence established: now, who will survive? J Clin Oncol 2002;20:3188-90.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh, PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-6.
5. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-5.
6. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76: 576-81.
7. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997;15:230-8.
8. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-7.
9. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73.
10. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48:629-33.
11. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel: Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1996;48:773-7.
12. Sun L, Gancarczyk K, Paquette EL, McLeod DG, Kane C, Kusuda L, et al. Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urol Oncol 2001;6:203-9.
13. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167:112-6.
14. Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology. Philadelphia (PA): Lea & Febiger; 1977. p. 171-87.
15. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997;24:389-94.
16. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. American Joint Committee on Cancer, manual for staging cancer. 6th ed. New York (NY): Springer-Verlag; 2002. p. 337-46.
17. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
18. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
19. Gaynor JJ, Feur EJ, Tan CC, Wu DH, Little CR, Straus DJ, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-500.
21. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med 1993;12:2377-82.
22. Davison AC, Hinkley DV, editors. Bootstrap methods and their application. Cambridge (UK): Cambridge University Press; 1997. p. 346-52.
23. Neter J, Wasserman W, Kutner M, editors. Simultaneous inferences and other topics in regression analysis-1. In: Applied linear regression models. Homewood (IL): Richard D. Irwin; 1983. p. 150-3.
24. D'Amico AV, Moul J, Carroll P, Sun L, Lubeck D, Chen M. Cancer-specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Clin Oncol 2003; 21:2163-72.
25. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997;16:1515-27.
26. Klein JP, Moeschberger ML, editors. Techniques for censored and truncated data in survival analysis. New York (NY): Springer-Verlag; 1997. p. 229-81.
27. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology 2001;15:1049-59.
28. Kattan MW, Easthan JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
29. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-1507.
30. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001;166: 1322-7.
31. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant therapy trials. J Clin Oncol 2000; 18:3240-6.
32. Biomarkers Definitions Working Group. Biomarkers and surrogate end-points: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
33. Fleming TR, Demets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
34. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167-78.
35. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J Infect Dis 1997;175:237-46.
36. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997;16:1965-82.
37. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments [published erratum appears in Biometrics 2000;56(1):324]. Biometrics 1998;54:1014-29.